In contrast to other antidiabetic drugs (including sulfonylurea, insulin, thiazolidinediones and incretin-based therapies) that may show an increased risk of cancer [10-16], metformin was first noted to be associated with a reduced risk of cancer in an observational study in 2005 [17]. Here, INS is linked to cancer.